Local Government Mandate Statement Kentucky Legislative Research Commission 2024 Regular Session

Part I: Measure Information

Bill Request #: 1792			
Bill #: HB 534 HCS 1			
Document ID #: <u>7412</u>			
Bill Title: AN ACT relating to addiction treatment.			
Sponsor: Representative Robert Duvall			
Unit of Government:	X City	X County	X Urban-County Unified Local
	X Charter County	X Consolidated Local	
Office(s) Impacted: All offices that offer health insurance for their employees.			
Requirement: X Mandatory Optional			
Effect on Powers & Duties:	Modifies Existing	X Adds New Eli	minates Existing

Part II: Bill Provisions and the Estimated Fiscal Impact Relating to Local Government

Section 2 of HB 534 amends KRS 304.17A-611 to prohibit health benefit plans from conducting a prospective or concurrent review for a prescription drug that contains an opioid antagonist.

HB 534 may have an indeterminable and likely negligible impact on local

governments. There are already drugs with similar prohibitions that currently exist— Methadone, Buprenorphine, and Naltrexone. By preventing health benefit plans from conducting prospective or concurrent reviews for prescriptions drug that contains an opioid antagonist, there may be a smaller administrative burden on health benefit plans cutting wait times for patients with prescriptions for those drugs; however, that is unknown at this time.

LRC staff also reached out to the Kentucky Association of Counties (KACo). If KACo provides information this mandate statement may be amended.

Data Source(s): <u>LRC Staff</u>

 Preparer:
 Bart Liguori (MS)
 Reviewer:
 KHC
 Date:
 2/29/24